 NEWTON, Mass., June 2, 2021 PRNewswire -- Karyopharm Therapeutics Inc. Nasdaq: KPTI, a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that on May 26, 2021 the UKs Medicines Healthcare Products Regulatory Agency MHRA granted conditional marketing authorization for NEXPOVIO selinexor, the Companys first-in-class, oral Selective Inhibitor of Nuclear Export SINE medicine, in combination with dexamethasone for the treatment of multiple myeloma in adult patients who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, two immunomodulatory agents, and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy. 